您使用提示模式 关闭
为了方块之间的快速移动

组织机构: Regeneron
LEI 549300RCBFWIRX3HYQ56

机构名称
Regeneron Pharmaceuticals Inc
国家名称
美国
注册登记国
美国
行业
药品生产和生物技术
债券负债
2.000 百万 USD

探索最全面的数据库

80 万

债券

超过 400

定价来源

8 万

股票

9 千

ETF

以最有效的方式跟踪您的投资组合
债券筛选器
观察列表
Excel 附加组件

最新数据在

卖价

查询已发送
无法访问
信息提供者所提供的报价仅供参考。

简介

Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.

奖项

相关文件

股票

最近一次的发行

债券负债 (按货币)

代码

  • LEI
    549300RCBFWIRX3HYQ56
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0000872589
  • EIN
    13-3444607

信用和 ESG 评级

宏观经济指数

你必须 注册 才能获得访问权